DMAAR vs FRT · $1.8M cap vs rev $1.28B
Drugs Made In America Acquisition Corp. Rights (DMAAR) versus FRT (FRT) — a side-by-side from cached financials, not a winner call.
Drugs Made In America Acquisition Corp. Rights (DMAAR) common stock listed on US.
FRT (FRT) common stock.
DMAAR does not have a complete income-statement cache yet.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
DMAAR currently screens at market cap $1.8M. FRT currently screens at market cap $0.
Not investment advice. Open the DMAAR and FRT stock pages for the full models.
Not investment advice.